Trials / Terminated
TerminatedNCT01483586
Safety and Efficacy of Kanglaite Gelcaps in Prostate Cancer
Efficacy and Safety of Oral Kanglaite (KLTc)in Men With Prostate Cancer: Randomized, Dose-Ranging Study of the Effects of KLTc on Prostate Specific Antigen (PSA) Doubling Time Among Men With Rising PSA Levels After Definitive Local Therapy
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 90 (actual)
- Sponsor
- KangLaiTe USA · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This research is being done to evaluate the safety and efficacy of the investigational Kanglaite gelcap (KLTc) on PSA in men with prostate cancer when given for twelve months.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | kanglaite gelcap | 3 KLTc gelcap capsules four times a day throughout the study (12 months). Each gelcap contains .45g KLT per capsule |
| DRUG | Kanglaite gelcap | 6 KLTc gelcaps taken four times a day throughout the study (12 months). Each gelcap contains .45g KLT |
Timeline
- Start date
- 2011-11-01
- Primary completion
- 2013-12-01
- Completion
- 2013-12-01
- First posted
- 2011-12-01
- Last updated
- 2014-04-14
Locations
5 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01483586. Inclusion in this directory is not an endorsement.